Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes
Get Live Data
70.00    0.00 (0.00%)
Bid:
69.00
Ask:
71.00
Spread: 2.00 (2.899%)
Market Cap: £318.58m
AVCT Live PriceLast checked at - London Stock Exchange

Intraday Avacta Group Share Chart

Directorate Appointment

9 Nov 2007 16:59

Avacta Group plc Board Appointment

Avacta Group plc ("Avacta" or the "Company"), which develops detection and analysis technology aimed at the biopharmaceutical, defence & security and clinical diagnostics markets, is pleased to announce the appointment of Russell Hodgetts to the Board of Directors, with effect from 10 July 2007.

Russell Winston Hodgetts, 36, has been Chief Operating Officer of Avacta since October 2005, and has a wealth of experience in strategic business development and group operations. Prior to joining Avacta he worked for Techtran Group Limited where he helped guide the commercialization and business development of companies created from University of Leeds research and intellectual property.

He currently oversees the development of the analytical services division of the Company in addition to being responsible for group operations.

Russell Hodgetts is the beneficial owner of 9,847,912 ordinary shares of 0.1p each in the capital of the Company ("Ordinary Shares"), representing approximately 1.27 per cent. of the issued share capital of the Company and 1,804,568 options to acquire Ordinary Shares at an exercise price of 2.25p per share.

He is also a director of Avacta Analytical Limited.

Russell Hodgetts was named Russell Beckett until family circumstances led to his name being changed when aged 11.

There are no other disclosures required by paragraph (g) of Schedule 2 of the AIM Rules for Companies.

Professor Alastair Smith, Chief Executive, Avacta Group plc, commented:

"Russell has been an integral part of the development of Avacta over the past two years and his focus on continued growth has been central to the success of Avacta Analytical Ltd. We are pleased to welcome him to the Board and will continue to draw on his knowledge and drive to ensure that Avacta maintains its current path of development and innovation."

9 November 2007EnquiriesAvacta Group plc Tel: 0870 835 4367 Alastair Smith, Chief Executive WH Ireland Limited Tel: 0161 832 2174 David Youngman/Robin Gwyn BankOra Limited Tel: 020 7562 4713 Henry Turcan/Michael Brennan Nexus Financial Ltd Tel: 020 7451 7050 Nicholas Nelson/Kathy Boate nicholas.nelson@nexusgroup.co.uk

AVACTA GROUP PLC
Date   Source Headline
28th Apr 20157:00 amRNSHalf Yearly Report
8th Apr 20157:00 amRNSNotice of Results
23rd Mar 20157:00 amRNSDrug discovery partnership
23rd Mar 20157:00 amRNSIssue of Equity
12th Feb 20157:00 amRNSSale of Optim Trade and Assets
9th Feb 20157:00 amRNSAffimer Development Contract with Protatonce
23rd Jan 20152:31 pmRNSResult of AGM
23rd Jan 20157:00 amRNSTrading Statement
16th Jan 20157:00 amRNSCommercial Partnership in the Agri-bio Market
6th Jan 20157:00 amRNSIssue of Equity
22nd Dec 20147:00 amRNSPosting of Annual Report & Accounts and AGM Notice
16th Oct 20147:00 amRNSFinal Results
30th Sep 20147:00 amRNSAffimer On-line Catalogue Launch
29th Sep 20147:00 amRNSInvestor Briefing
22nd Sep 20147:00 amRNSAppointment of a Senior Executive
4th Aug 20147:00 amRNSNew OPTIM Software and Hardware
1st Aug 20147:00 amRNSPre Close Trading Update
15th Jul 20147:00 amRNSMajor Japanese Distributor Signed
13th Jun 201411:04 amRNSHolding(s) in Company
2nd Jun 20141:04 pmRNSHolding(s) in Company
2nd Jun 20147:00 amRNSAvacta Secures Funding Award
30th May 20144:37 pmRNSHolding(s) in Company
30th May 20142:52 pmRNSHolding(s) in Company
29th May 20144:21 pmRNSHolding(s) in Company
28th May 20147:00 amRNSAvacta Life Sciences Exhibits Affimers at PEGS
23rd May 201412:53 pmRNSResult of General Meeting
21st May 20145:36 pmRNSHolding(s) in Company
14th May 20147:00 amRNSIssue of Equity
9th May 20144:19 pmRNSDirector's dealing
9th May 20147:00 amRNSAvacta Announce Collaboration with UbiQ Bio BV
7th May 20147:00 amRNSConditional Placing
23rd Apr 20147:00 amRNSInterim Results
14th Apr 20147:00 amRNSAvacta Launch Pancreatitis Test for Dogs
20th Mar 20147:00 amRNSAffimers : Technical and Commercial Update
11th Mar 20147:00 amRNSNotice of Interim Results
24th Feb 20147:00 amRNSDirectors Dealings
5th Feb 20147:00 amRNSNew Board Appointment
4th Feb 20149:29 amRNSHolding(s) in Company
3rd Feb 20147:00 amRNSAvacta Initiates Collaboration with University
28th Jan 20147:00 amRNSAvacta Life Sciences Launches Affimers Web Site
24th Jan 20142:57 pmRNSResult of AGM
24th Jan 20147:00 amRNSAGM Statement
20th Jan 20147:00 amRNSIssue of Equity
13th Jan 20147:00 amRNSInvestor teach-in
23rd Dec 20132:59 pmRNSNotice of AGM and Report and Accounts
23rd Dec 20137:00 amRNSBoard Appointment
27th Nov 201310:01 amRNSNew Canine Lymphoma Blood Test Launched
1st Nov 20137:00 amRNSIssue of Equity
24th Oct 20137:00 amRNSPreliminary Results
17th Oct 20137:00 amRNSFirst therapeutic licensing agreement for Affimers

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.